Articles from Imperative Care, Inc.

Imperative Care, Inc. today announced U.S. Food and Drug Administration (FDA) 510(k) clearance and first patient cases with the latest advancement in ischemic stroke treatment – the novel Zoom 7X Catheter for aspiration thrombectomy procedures.

Imperative Care, Inc. today announced a late-breaking abstract with data from the Imperative Trial evaluating aspiration with the Zoom System in stroke patients with M2 occlusions, presented at the Society of NeuroInterventional Surgery (SNIS) 2025 22nd Annual Meeting in Nashville, Tenn.

Imperative Care, Inc. today announced the appointment of Tyler Binney to the company’s Board of Directors, effective immediately.

Imperative Care, Inc. today announced the completion of patient enrollment in its SYMPHONY-PE Study (NCT06062329), a pivotal Investigational Device Exemption (IDE) trial evaluating the safety and efficacy of the company’s Symphony Thrombectomy System for the treatment of acute pulmonary embolism (PE), a life-threatening condition caused by blood clots blocking an artery in the lungs.

Imperative Care, Inc. today announced the Zoom Stroke System has been further expanded with the launch of the Zoom DuoPort technology, which allows physicians to use the novel Continuous Dual Aspiration Technique (CDAT) on two Zoom Aspiration Catheters simultaneously from a single vacuum source. CDAT empowers physicians with enhanced aspiration control and immediate clot feedback from within the sterile field with two Zoom PODs.

Imperative Care, Inc. today announced the appointment of Todd Van Horn as Chief Financial Officer.

Imperative Care, Inc. today announced it will fund an investigator-initiated, multicenter, randomized, controlled clinical trial comparing aspiration thrombectomy with the Zoom Stroke System plus best medical treatment versus best medical treatment alone. The study will examine treatments in patients suffering from acute ischemic stroke due to a primary occlusion of the M2 segment of the middle cerebral artery within eight hours of symptom onset.

Imperative Care, Inc. today announced U.S. Food and Drug Administration (FDA) 510(k) clearance of the 82cm version of its Symphony™ 16F Catheter, the company’s latest innovation designed to elevate care for patients with venous thrombosis, a serious condition caused by a blood clot forming in the veins of the legs or abdomen that can have a life-threatening impact if left untreated.

Imperative Care, Inc. today announced that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance of the company’s Zoom System, making it the first comprehensive stroke thrombectomy system to include large-bore .088” catheters indicated for both access and aspiration when used with a Zoom Catheter. This clearance expands Imperative Care's current portfolio of .035” - .071” aspiration catheters to now include the Zoom .088” catheters – Zoom 88, Zoom 88 Support and TracStar – for aspiration as part of the Zoom System.

Imperative Care, Inc., a medical technology company developing connected innovations to elevate care for people affected by stroke and other ischemic diseases, today announced the initial close of an oversubscribed Series E financing.

Imperative Care, Inc. today announced that late-breaking data from the Imperative Trial were presented at the Society of NeuroInterventional Surgery (SNIS) 2024 21st Annual Meeting in Colorado Springs. The prospective, multi-center clinical trial evaluated the clinical benefits of the Zoom Reperfusion System, including aspiration with 0.088” catheters for the treatment of ischemic stroke.* Data from the clinical trial were presented by Dr. William Mack, M.D., Professor of Neurosurgery at the Keck School of Medicine, University of Southern California and Co-Principal Investigator of the Imperative Trial.

Imperative Care, Inc., today announced U.S. Food and Drug Administration (FDA) 510(k) clearance of its Zoom™ 6F Insert Catheters, the company’s latest innovation in elevating stroke care and the first insert catheters developed specifically for ischemic stroke procedures. The company also announced the successful completion of the first case with the Zoom 6F Insert Catheters, which was performed by Dr. Dana Tomalty at Huntsville Hospital in Huntsville, Alabama.

Imperative Care, a medical technology company developing connected innovations to elevate care for people affected by stroke and other ischemic diseases, today announced the appointment of Chuck Alpuche as Chief Operating Officer (COO), Peter Griffin as Senior Vice President of Operations, Scott Elliott as Chief Legal Officer (CLO), and Daniel Davis as Chief Strategy Officer (CSO).

Imperative Care, a medical technology company developing connected innovations to elevate care for people affected by stroke and other ischemic diseases, today announced the initiation of a first-in-human clinical study for its novel stent system designed to only require single antiplatelet therapy for patients undergoing stent-assisted treatment of wide-neck intracranial aneurysms.

Imperative Care, a medical technology company developing connected innovations to elevate care for people affected by stroke and other ischemic diseases, today announced the publication of clinical data in Interventional Neuroradiology (INR) of the Zoom Aspiration Catheters in patients with large and medium vessel occlusions.

Imperative Care, Inc., a medical technology company elevating care for people affected by stroke and other ischemic diseases, today announced a new organizational structure designed to accelerate the company’s growth across its businesses.

Imperative Care, a medical technology company developing connected innovations to elevate care for people affected by stroke and other ischemic diseases, today announced that late-breaking data from the Neurovascular Quality Initiative-Quality Outcome Database (NVQI-QOD) evaluating the Zoom Stroke Solution were presented at the Society of NeuroInterventional Surgery (SNIS) 2023 20th Annual Meeting in San Diego, Calif.

Imperative Care, a medical technology company developing connected innovations to elevate care for people affected by stroke and other ischemic diseases, today announced that new data from studies evaluating the Zoom Stroke Solution for the treatment of ischemic stroke will be presented at the Society of NeuroInterventional Surgery (SNIS) 2023 20th Annual Meeting taking place July 31-August 4 in San Diego, Calif.

Imperative Care, Inc., a medical technology company elevating care for people affected by stroke and other ischemic diseases, today announced the appointment of Kirsten Carroll as Chief Executive Officer of Kandu Health, Inc., a digital health startup company with the aim of improving quality of life for people affected by stroke. The company also announced the successful enrollment of the first 50 stroke survivors in its program and the appointments of Chief Financial Officer Stefan Heuser and Senior Vice President of Commercialization, Clayton Duncan.

Imperative Care, a medical technology company developing connected innovations to elevate care for people affected by stroke and other ischemic diseases, today announced the publication of early clinical data in the Journal of Neurointerventional Surgery (JNIS) from a single-center evaluation of the Zoom™ RDL Radial Access System.

Imperative Care, Inc. a medical technology company developing connected innovations to elevate care for people affected by stroke and other ischemic diseases, today announced the appointment of Shacey Petrovic to the company’s Board of Directors, effective immediately.

Imperative Care, Inc., today announced U.S. Food and Drug Administration (FDA) 510(k) clearance of its Zoom™ RDL Radial Access System, the company’s latest innovation in elevating stroke care and the first radial access platform developed specifically for ischemic stroke treatment.

Imperative Care, Inc. today announced that new data evaluating the utility of the Zoom Stroke Solution were presented at the World Federation of Interventional and Therapeutic Neuroradiology (WFITN) 2022 Annual Meeting in Kyoto.

Imperative Care, Inc. today announced that new data from studies evaluating the utility of the Zoom Stroke Solution were presented at the Society of NeuroInterventional Surgery (SNIS) 2022 19th Annual Meeting in Toronto.

Imperative Care, Inc. today announced that new data from studies evaluating the utility of the Zoom Stroke Solution for the treatment of ischemic stroke will be presented at the Society of NeuroInterventional Surgery (SNIS) 2022 19th Annual Meeting taking place July 25-29 in Toronto.

Imperative Care, Inc. today announced the appointment of Henrietta Fore and Stacy Enxing Seng to the company’s Board of Directors, effective immediately.

Imperative Care, Inc. today announced that 10,000 patients have been treated in the U.S. with its technologies for stroke since 2020. The company’s current portfolio includes the Zoom Stroke Solution™ and TracStar® LDP technologies for ischemic and hemorrhagic stroke, which received FDA 510(k) clearance in 2019. With a physician-driven approach to innovation, the company is working to advance every aspect of the stroke procedure – from access through treatment – to empower clinicians and their staff with the right tools to continuously improve patient outcomes.

Truvic Medical, Inc., a wholly owned subsidiary of Imperative Care, Inc., today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the Prodigy™ Thrombectomy System, designed for the treatment of peripheral vascular thrombus.

Imperative Care, Inc. today announced the launch of its Zoom POD™ Aspiration Tubing, the company’s latest innovation in elevating stroke care. The Zoom POD is the newest addition to Imperative Care’s Zoom Stroke Solution™, the company’s ischemic stroke product portfolio that includes the Zoom 88 Large Distal Platform for neurovascular access, four Zoom Aspiration Catheters in various sizes, and the Zoom Pump with accessories.

Imperative Care, Inc. announced today that the first patient has been enrolled in the Imperative Trial. This prospective, multi-center clinical trial is the first study designed to evaluate the clinical benefits of direct aspiration for the treatment of ischemic stroke with the Zoom 88 Large Distal Platform, which is currently FDA cleared for neurovascular access. Additionally, the trial will gather data on the clinical benefits of the full Zoom Stroke Solution™, the company’s ischemic stroke product portfolio that includes the Zoom 88 Large Distal Platform for neurovascular access, four Zoom aspiration catheters in various sizes, and a pump with accessories.

Imperative Care, Inc. today announced three appointments to the company’s Board of Directors with the addition of Holly Sheffield, Hank Plain, and James Rogers.

Imperative Care, Inc. today announced that it has closed a $260 million Series D financing led by D1 Capital Partners L.P. New investors HealthCor Investments LLC and Innovatus Capital Partners, LLC also joined the round. Existing Imperative Care investors Ally Bridge Group, Bain Capital Life Sciences, Ascension Ventures, Delos Capital, Rock Springs Capital, and Amed Ventures participated in the financing. James Rogers from D1 will join Imperative Care’s Board of Directors.